DAWN
Income statement / Annual
Last year (2024), Day One Biopharmaceuticals, Inc.'s total revenue was $131.16 M,
and the percentage change from the previous year is not available.
In 2024, Day One Biopharmaceuticals, Inc.'s net income was -$95.50 M.
See Day One Biopharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$131.16 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$5.28 M
|
$383,000.00
|
$531,000.00
|
$199,000.00
|
$155,000.00
|
$0.00
|
| Gross Profit |
$125.88 M
|
-$383,000.00
|
-$531,000.00
|
-$199,000.00
|
-$155,000.00
|
$0.00
|
| Gross Profit Ratio |
0.96
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$227.70 M
|
$130.52 M
|
$85.62 M
|
$43.58 M
|
$9.10 M
|
$13.90 M
|
| General & Administrative Expenses |
$0.00
|
$75.54 M
|
$61.29 M
|
$29.16 M
|
$4.68 M
|
$1.01 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$115.45 M
|
$75.54 M
|
$61.29 M
|
$29.16 M
|
$4.68 M
|
$1.01 M
|
| Other Expenses |
$0.00
|
$1.00
|
-$18,000.00
|
-$15,000.00
|
-$31,000.00
|
-$2,000.00
|
| Operating Expenses |
$343.15 M
|
$206.06 M
|
$146.91 M
|
$72.74 M
|
$13.78 M
|
$14.91 M
|
| Cost And Expenses |
$348.43 M
|
$206.06 M
|
$146.91 M
|
$72.74 M
|
$13.78 M
|
$14.91 M
|
| Interest Income |
$0.00
|
$17.19 M
|
$4.75 M
|
$4,000.00
|
$30.00
|
$2,077.00
|
| Interest Expense |
$0.00
|
$0.00
|
$4.75 M
|
$4,000.00
|
$30,000.00
|
$2.08 M
|
| Depreciation & Amortization |
$0.00
|
$383,000.00
|
$531,000.00
|
$199,000.00
|
$155,000.00
|
$14.91 M
|
| EBITDA |
-$217.27 M |
-$206.06 M |
-$141.65 M |
-$72.56 M |
-$43.66 M |
-$2,000.00 |
| EBITDA Ratio |
-1.66
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-1.66
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$128.92 M
|
$17.15 M
|
$4.73 M
|
-$11,000.00
|
-$30.06 M
|
-$2.08 M
|
| Income Before Tax |
-$88.35 M
|
-$188.92 M
|
-$142.18 M
|
-$72.75 M
|
-$43.84 M
|
-$16.98 M
|
| Income Before Tax Ratio |
-0.67
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$7.14 M
|
$0.00
|
-$10.01 M
|
-$2.31 M
|
-$3.34 M
|
-$2.27 M
|
| Net Income |
-$95.50 M
|
-$188.92 M
|
-$132.18 M
|
-$70.44 M
|
-$40.51 M
|
-$14.71 M
|
| Net Income Ratio |
-0.73
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.02 |
-2.37 |
-2.02 |
-1.14 |
-0.65 |
-0.24 |
| EPS Diluted |
-1.02 |
-2.37 |
-2.02 |
-1.14 |
-0.65 |
-0.24 |
| Weighted Average Shares Out |
$93.62 M
|
$79.77 M
|
$65.47 M
|
$61.95 M
|
$61.93 M
|
$61.93 M
|
| Weighted Average Shares Out Diluted |
$93.62 M
|
$79.77 M
|
$65.47 M
|
$61.95 M
|
$61.93 M
|
$61.93 M
|
| Link |
|
|
|
|
|
|
